Hainan Shuangcheng Pharmaceut (002693) — Net Asset Quality Index
Hainan Shuangcheng Pharmaceut (002693) has a Net Asset Quality Index of 51.5% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥816.14 Million minus total liabilities of CN¥396.21 Million yields net assets of CN¥419.93 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 002693 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hainan Shuangcheng Pharmaceut Net Asset Quality Index Over Time (2009–2025)
This chart shows how Hainan Shuangcheng Pharmaceut's Net Asset Quality Index has evolved across 17 annual periods from 2009 to 2025. As of March 2026, the index stands at 51.5%, representing net assets of CN¥419.93 Million against total assets of CN¥816.14 Million CNY. See 002693 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below presents the year-by-year Net Asset Quality Index for Hainan Shuangcheng Pharmaceut from 2009 to 2025, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hainan Shuangcheng Pharmaceut stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 50.9% | CN¥420.53 Million | CN¥825.78 Million | CN¥405.25 Million | ▼ -1.6 pp |
| 2024 | 52.5% | CN¥411.61 Million | CN¥783.87 Million | CN¥372.26 Million | ▼ -11.9 pp |
| 2023 | 64.4% | CN¥517.65 Million | CN¥803.25 Million | CN¥285.60 Million | ▲ +0.7 pp |
| 2022 | 63.8% | CN¥580.94 Million | CN¥911.02 Million | CN¥330.08 Million | ▼ -2.6 pp |
| 2021 | 66.3% | CN¥566.75 Million | CN¥854.56 Million | CN¥287.80 Million | ▲ +0.4 pp |
| 2020 | 65.9% | CN¥598.31 Million | CN¥907.68 Million | CN¥309.37 Million | ▼ -5.4 pp |
| 2019 | 71.3% | CN¥678.26 Million | CN¥950.98 Million | CN¥272.72 Million | ▲ +11.5 pp |
| 2018 | 59.8% | CN¥669.69 Million | CN¥1.12 Billion | CN¥450.56 Million | ▲ +4.5 pp |
| 2017 | 55.3% | CN¥761.71 Million | CN¥1.38 Billion | CN¥615.41 Million | ▲ +7.9 pp |
| 2016 | 47.5% | CN¥553.13 Million | CN¥1.17 Billion | CN¥612.40 Million | ▼ -12.4 pp |
| 2015 | 59.8% | CN¥927.61 Million | CN¥1.55 Billion | CN¥622.56 Million | ▼ -34.9 pp |
| 2014 | 94.7% | CN¥893.55 Million | CN¥943.54 Million | CN¥49.99 Million | ▼ -0.2 pp |
| 2013 | 94.9% | CN¥870.62 Million | CN¥917.04 Million | CN¥46.42 Million | ▼ -0.5 pp |
| 2012 | 95.4% | CN¥845.85 Million | CN¥886.65 Million | CN¥40.80 Million | ▲ +3.4 pp |
| 2011 | 92.0% | CN¥228.23 Million | CN¥248.06 Million | CN¥19.83 Million | ▲ +29.6 pp |
| 2010 | 62.4% | CN¥157.82 Million | CN¥252.73 Million | CN¥94.92 Million | ▼ -17.2 pp |
| 2009 | 79.7% | CN¥77.95 Million | CN¥97.85 Million | CN¥19.91 Million | — |